MELBOURNE, Australia , May  13, 2026  (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (NASDAQ:PPCB) (&#34;Propanc&#34; or the &#34;Company&#34;), a biopharmaceutical company focused on developing novel treatments for chronic diseases,

PPCB

Propanc Biopharma Implements Reverse Stock Split to Support Continued Nasdaq Listing and Growth Plans

PPCB Approves 1-for-25 Reverse Stock Split to Meet Nasdaq Requirements

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>MELBOURNE, Australia , May  13, 2026  (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (NASDAQ:PPCB) (&amp;#34;Propanc&amp;#34; or the &amp;#34;Company&amp;#34;), a biopharmaceutical company focused on developing novel treatments for chronic diseases,</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Propanc Biopharma, Inc. (PPCB) has announced a 1-for-25 reverse stock split, effective May 18, 2026, aimed at regaining compliance with Nasdaq&#039;s listing standards. This action is crucial for restoring investor confidence and could provide a better market perception as the company progresses its lead cancer treatment candidate, PRP, into clinical studies.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>PPCB approved a 1-for-25 reverse stock split effective May 18, 2026.</li><li>Outstanding shares will reduce from 56.9M to approximately 2.3M shares.</li><li>The split aims to comply with Nasdaq&#039;s $1 minimum bid price requirement.</li><li>CEO forecasts advancement of lead asset PRP into Phase 1b cancer study.</li><li>No change in par value of the stock post-split.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Propanc Biopharma, Inc. (PPCB)</strong>: Focus on meeting Nasdaq requirements through share consolidation.</li></ul>
  </section>

  <section data-block="category">
    <h3>Corporate Developments</h3>
    <p>This falls under &#039;Corporate Developments&#039; as it directly relates to the company&#039;s compliance actions with market regulations, critical for its future trading viability.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>The reverse stock split could improve PPCB&#039;s stock price perception.</li><li>Compliance with Nasdaq may stabilize PPCB&#039;s trading environment.</li><li>Advancement in PRP clinical trials could generate positive investor sentiment.</li><li>Future announcements on clinical trial results may strongly influence PPCB&#039;s valuation.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Reverse stock split approved on March 16, 2026.</li><li>Effective date of the split is May 18, 2026.</li><li>Outstanding shares will reduce from 56,959,280 to 2,278,372.</li><li>New CUSIP number post-split will be 74346N800.</li><li>PPCB&#039;s lead candidate, PRP, targets cancer recurrence management.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>PPCB may experience increased volatility post-split, but renewed Nasdaq compliance could attract investors.</p>
  </section>
</section>


<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css"></link><p>MELBOURNE, Australia , May  13, 2026  (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/PPCB">PPCB</a>) ("Propanc" or the "Company"), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, today announced that its Board of Directors on March 16, 2026, approved a 1-for-25 reverse stock split of the Company&#39;s issued and outstanding shares of common stock, par value $0.001 per share, (the "Reverse Stock Split"). The Reverse Stock Split is anticipated to be effective as of the open of the market May 18, 2026.</p>  <p>As a result of the Reverse Stock Split, every 25 pre-split shares of Company common stock outstanding will automatically combine into one new share of common stock without any action on the part of the holders, and the number of outstanding common shares will be reduced from approximately 56,959,280 million shares (as of May 6, 2026) to approximately 2,278,372 million shares on a pro forma basis. Fractional shares resulting from the Reverse Stock Split will be rounded up to the nearest whole share on a per shareholder basis (per participant basis at DTC). The Reverse Stock Split will not affect the par value of the Company's common stock.</p>  <p>The Company anticipates that the effective time of the Reverse Stock Split will be before market open on May 18, 2026, with the common stock trading on a post-split basis under the Company&#39;s existing trading symbol, "PPCB," with a new CUSIP number, 74346N800. Securities Transfer Corporation, the Company's transfer agent, will act as the exchange agent for the Reverse Stock Split.</p>  <p>"The Reverse Stock Split is being implemented to enable the Company to expeditiously restore compliance with the continued listing standards of the Nasdaq Stock Market and Nasdaq's $1.00 minimum bid price requirement and growth plans. We look forward to providing further updates as the Company advances its lead asset, PRP, to a world-first, Phase 1b clinical study in advanced cancer patients suffering from solid tumors," said Mr. James Nathanielsz, Propanc's Chief Executive Officer.</p>  <p><strong>About Propanc Biopharma, Inc.</strong></p>  <p>Propanc Biopharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/PPCB">PPCB</a>) is developing a novel approach to preventing cancer recurrence and metastasis by targeting and eradicating cancer stem cells through proenzyme activation. The Company's lead product candidate, PRP, is designed to address the underlying drivers of cancer proliferation and spread.</p>  <p><strong>More information:</strong> <a href="https://www.globenewswire.com/Tracker?data=bH-jh9O0KyxNCceTg29bpt5Tj49PPpZgNleilKn2s3QNoaYEnpb3NRK7UahHw4fqP_2tZ11bmPYnUoCbTsRI7w==" rel="nofollow" target="_blank">www.propanc.com</a></p>  <p><strong>Forward-Looking Statements</strong></p>  <p>All statements in this press release that are not historical are forward-looking statements, including, among other things, statements relating to the Company's expectations regarding its market position and market opportunity, expectations and plans as to its product development, manufacturing and sales, and relations with its partners and investors, made in reliance upon the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are not historical facts but rather are based on the Company's current expectations, estimates, and projections regarding its business, operations and other similar or related factors. Words such as "may," "will," "could," "would," "should," "anticipate," "predict," "potential," "continue," "expect," "intend," "plan," "project," "believe," "estimate," and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond the Company's control. Forward-looking statements are not guarantees of future actions or performance. Actual results may differ materially from those in the forward-looking statements because of several factors, including, without limitation, risks and uncertainties related to market conditions, as well as those risks described under "Risk Factors" in the prospectus related to the proposed offering and those described in the Company's filings with the SEC. The Company undertakes no obligation to revise or update information in this release to reflect events or circumstances in the future, even if new information becomes available.</p>  <p><strong>Company:</strong><br></br>Propanc Biopharma, Inc.<br></br>James Nathanielsz</p>  <p>+61-3-9882-0780</p>  <p><a href="https://www.globenewswire.com/Tracker?data=aoEiQgEjY1F7sIf8mRH79dLmHkHP1fLHIX40WR-HCy8qsUNGi6skwKtiRCBddhdu6mwfYdXyREa9FOEYHyREosj72_jdXWeNGRNHQ2MlsVM=" rel="nofollow" target="_blank"><u>info@propanc.com</u></a></p>  <p><strong>Investor Contact:</strong></p>  <p><a href="https://www.globenewswire.com/Tracker?data=JEdATOPyIJhg1a-gMSnhvv-ZW8g00b8QSFNxAFi_IO_KBFGL226YvphVwInVI4DemS-j4s_Weyj2qGUxVfFCeLgwK-kO-0bvWz0l7uK_UF8=" rel="nofollow" target="_blank"><u>irteam@propanc.com</u></a></p> <img alt="" class="__GNW8366DE3E__IMG" src="https://www.globenewswire.com/newsroom/ti?nf=OTcxOTI0MCM3NjAwNDMwIzIyOTExMTI="></img> <br></br><img alt="" src="https://ml.globenewswire.com/media/OWFkNGFlMzctYWNhNC00YWNjLTk5OWItMjE1NDdhNTM3OWFhLTEzMDI2NjItMjAyNi0wNS0xNC1lbg==/tiny/Propanc-Biopharma-Inc-.png" referrerpolicy="no-referrer-when-downgrade"></img><p><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/0de2a486-4708-45bf-a406-f462ad395dec"><img src="https://ml.globenewswire.com/media/0de2a486-4708-45bf-a406-f462ad395dec/small/propanc-logo-png.png" border="0" width="150" height="34" alt="Primary Logo"></img></a></p>

Propanc Biopharma, Inc. (PPCB) has announced a 1-for-25 reverse stock split, effective May 18, 2026, aimed at regaining compliance with Nasdaq's listing standards. This action is crucial for restoring investor confidence and could provide a better market perception as the company progresses its lead cancer treatment candidate, PRP, into clinical studies.

Propanc Biopharma Implements Reverse Stock Split to Support Continued Nasdaq Listing and Growth Plans

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Corporate Developments

Related News